DHEA Dosage: 25 mg, 50 mg, and What the Trials Used
Not medical advice. DHEA is a steroid hormone; this page reports the doses human trials used and what they found, so that a decision made with a clinician is made against the record. The DHEA hub covers what the trials showed and who should not take it.
Quick answer
25 to 50 mg once a day is the whole evidence base in healthy adults. Both doses restored young-adult DHEA-S within days in the pharmacokinetic study, with a blood half-life over 20 hours, so once a day is enough. 50 mg for a year in 280 people over 60 and 50 mg (women) or 75 mg (men) for two years at the Mayo Clinic are the long trials, and they found little: modest skin, bone-turnover and libido changes in women over 70 in the first, nothing on body composition, strength, insulin or quality of life in the second. Women convert more of it to testosterone and estradiol, so they start lower, at 10 to 25 mg, and see the androgenic side effects first.
21.3% of the shelf is dosed above the trials. Of the 350 DHEA labels filed with the NIH, 37.5% deliver 25 mg a serving and 27.1% 50 mg; 21.3% exceed 50 mg and 20.7% are 100 mg or more, a tier that is mostly 7-keto DHEA (18% of labels), a metabolite the DHEA trials do not cover. See the census →
Every DHEA dose with human trial data
| Setting | Dose | What it found | Source |
|---|---|---|---|
| Pharmacokinetics, healthy adults 60+ | 25 or 50 mg once daily | Half-life over 20 h; DHEA-S restored to young-adult levels; women convert more to active steroids than men | Legrain 2000 (24 people, 8 days) |
| Healthy adults 60 to 79, one year | 50 mg once daily | Modest skin, bone-turnover and libido changes, mostly in women over 70; no harmful accumulation | Baulieu 2000 (280 people) |
| Healthy elderly, two years | 50 mg women, 75 mg men, once daily | No effect on body composition, strength, insulin sensitivity or quality of life; small bone-density gains | Nair 2006 (87 men, 57 women) |
| Women with adrenal insufficiency | 25 to 50 mg once daily | Small quality-of-life gain (effect size 0.21); no effect on anxiety or sexual well-being | Alkatib 2009 (10 trials) |
| IVF poor responders, pre-treatment | 75 mg daily (25 mg three times), 6 to 12 weeks in most trials | Likely little or no difference to live birth (odds ratio 1.3) | Naik 2024 (9 trials, 1,433 women) |
| Midlife-onset depression, supervised | 90 mg then 450 mg daily, 3 weeks each | More responders than placebo in a crossover trial; a clinical lead, not a supplement dose | Schmidt 2005 (46 people) |
| Menopausal vaginal dryness (prescription, intravaginal) | 6.5 mg nightly, intravaginal | Improved cell maturation, pH and pain over 12 weeks with serum hormones unchanged | Labrie 2016 (325 vs 157 women) |
Two things stand out. The dose range in healthy adults is narrow, 25 to 75 mg, and the long trials at those doses did not find a functional benefit (Nair 2006, PMID 17050889). And the only doses above that, the 90 to 450 mg of the NIMH depression trial, were given for six weeks under psychiatric supervision to 46 people (Schmidt 2005, PMID 15699292); they are not a supplement dose and no label suggests them.
Why women take less
DHEA is converted to testosterone and estradiol inside tissues, and the pharmacokinetic study found the conversion of DHEA-S back to DHEA significantly greater in women than men, with the rise in estradiol concentrated in older women (Legrain 2000, PMID 10999810). The DHEAge trial saw the same pattern: the small rise in testosterone and estradiol was "particularly in women", and so were the effects (Baulieu 2000, PMID 10760294). That is why the Mayo trial dosed women at 50 mg and men at 75 mg, and why a woman starting DHEA starts at 10 to 25 mg: at 50 mg, oily skin, acne and facial hair are the common complaints. It is also why the women's androgen guideline recommends against routine use: across 1,188 postmenopausal women with normal adrenal function, DHEA did not significantly improve libido or sexual function at any dose (Elraiyah 2014, PMID 25279571; Wierman 2014, PMID 25279570). The exception is women with adrenal insufficiency, who make none of their own; there, 25 to 50 mg produced a small quality-of-life gain across 10 trials (Alkatib 2009, PMID 19773400).
Once a day, in the morning, with a blood test
Oral DHEA is quickly sulfated to DHEA-S, which acts as a reservoir and is slowly converted back; that gives unconjugated DHEA an apparent half-life over 20 hours and means a single morning dose, matching the adrenal rhythm, covers the day (Legrain 2000). Divided dosing appears only in the IVF protocols (25 mg three times a day for 6 to 12 weeks), and the 2024 Cochrane review found that regimen likely makes little or no difference to live birth (Naik 2024, PMID 38837771). The test that matters is DHEA-S: before starting, to confirm it is low for age and sex, and at 4 to 8 weeks, to confirm it is back in the young-adult range and not above it. Restoring the range is all the trials did; exceeding it has no trial behind it and adds androgen and estrogen exposure.
We read 350 DHEA labels: where the doses sit
Original research350 DHEA labels from the NIH Dietary Supplement Label Database, 141 brands; milligrams read from the Supplement Facts row and multiplied by the maximum daily servings in the directions. 14 of 16 figures held in both halves of the census and only those are printed.
The median daily dose on the shelf is 50 mg and a quarter of labels sit at 25 mg a day or below. 37.5% of labels deliver exactly 25 mg a serving and 27.1% exactly 50 mg, so two-thirds of the shelf is inside the trial range. 11.5% are 10 mg or less, the tier a woman would start at, and only 0.9% are sold as a women's line. The other 21.3% exceed 50 mg a serving, and 20.7% deliver 100 mg or more; those are mostly 7-keto DHEA products (18% of all labels), sold at 100 mg twice a day for weight loss, which is a different molecule with no DHEA trial behind it.
| Item | Value (%) |
|---|---|
| 10 mg or less | 11.5% |
| 25 mg | 37.5% |
| 50 mg | 27.1% |
| More than 50 mg | 21.3% |
| 100 mg or more | 20.7% |
What did not hold
350 labels, split-half by label-id parity: 14 of 16 checks agreed. Not printed (2): median DHEA mg per serving; p75 daily mg. Open data at /dhea/best-overall.json (CC BY 4.0).
A product at each trial dose
Product links go to Amazon and we may earn a commission if you buy. It never changes which product we pick or what we say about it. How we choose.
All tracked products, ranked by cost per 25 mg, are on the best-overall page.
Frequently asked questions
How much DHEA should I take?
If a clinician has measured a low DHEA-S and agreed to a trial, the doses with human data are 25 and 50 mg once a day: 25 or 50 mg restored young-adult DHEA-S within days in the pharmacokinetic study, 50 mg was the one-year DHEAge dose for both sexes, and the two-year Mayo trial used 50 mg in women and 75 mg in men. Women convert more DHEA to testosterone and estradiol, which is why they start lower (10 to 25 mg) and why acne and oily skin at 50 mg are common in women and rare in men. Nothing above 75 mg has trial data in healthy adults.
Should I take DHEA in the morning or at night?
Morning, once a day. Oral DHEA has a blood half-life over 20 hours because it is stored as DHEA-S and slowly converted back, so a single dose covers the day, and the adrenals release it in the morning. Splitting the dose adds nothing; the only trials using divided doses were the IVF protocols (25 mg three times a day).
How much DHEA is too much?
Above 50 mg a day you are outside every trial in healthy adults except the men's arm of the Mayo study (75 mg). The 90 to 450 mg depression doses were given under psychiatric supervision for six weeks. On the 350 labels we read, 21.3% deliver more than 50 mg a serving and 20.7% deliver 100 mg or more; 18% of labels are 7-keto DHEA, which is what most of the 100 mg products are. 7-keto is a metabolite that is not converted to sex hormones, so it is neither a high dose of DHEA nor covered by the DHEA trials.
What dose of DHEA for women?
Lower than for men. Women start at 10 to 25 mg; the 50 mg trials in women reported more androgenic side effects (oily skin, acne, facial hair) than men at the same dose, and the meta-analysis of 1,188 postmenopausal women with normal adrenal function found no significant benefit for libido or sexual function at any dose. The women's androgen guideline recommends against routine DHEA. Only 0.9% of labels are sold as a women's line, so the practical route is a plain 10 mg or 25 mg product.
Do I need blood tests?
Yes, if you take it at all: a DHEA-S level before starting (to confirm it is low for your age and sex) and again at 4 to 8 weeks, plus testosterone and estradiol in women if side effects appear. A supplement that restores DHEA-S to the young-adult range has done what it can do; raising it above that range has no trial support and adds androgen exposure.
Related guides
- DHEA: what the trials found, and what the shelf sells
- Best DHEA supplement, ranked by cost per 25 mg
- Tongkat ali dosage guide
- Boron dosage guide
Sources
- Legrain S, et al. “Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects.” J Clin Endocrinol Metab. 2000. PMID: 10999810
- Baulieu EE, et al. “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study.” Proc Natl Acad Sci USA. 2000. PMID: 10760294
- Nair KS, et al. “DHEA in elderly women and DHEA or testosterone in elderly men.” N Engl J Med. 2006. PMID: 17050889
- Alkatib AA, et al. “DHEA treatment effects on quality of life in women with adrenal insufficiency: a systematic review and meta-analysis.” J Clin Endocrinol Metab. 2009. PMID: 19773400
- Elraiyah T, et al. “The benefits and harms of systemic DHEA in postmenopausal women with normal adrenal function.” J Clin Endocrinol Metab. 2014. PMID: 25279571
- Wierman ME, et al. “Androgen therapy in women: a reappraisal. An Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab. 2014. PMID: 25279570
- Naik R, et al. “Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction.” Cochrane Database Syst Rev. 2024. PMID: 38837771
- Schmidt PJ, et al. “Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.” Arch Gen Psychiatry. 2005. PMID: 15699292
- Labrie F, et al. “Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness.” Menopause. 2016. PMID: 26731686
- NIH Office of Dietary Supplements. Dietary Supplement Label Database. dsld.od.nih.gov (labels retrieved 2026-09-18).